<DOC>
	<DOCNO>NCT02778464</DOCNO>
	<brief_summary>When woman rheumatoid arthritis become pregnant 75 % go remission , despite stop medication . This phenomenon well understood see inflammatory condition . Once give birth often relapse . Bacteria stool inside gut ability effect immune system beneficial bacteria know regulate inflammatory component immune system . Gut bacteria also know alter significantly pregnancy inflammatory condition low level beneficial bacteria associate disease like ulcerative colitis . There significant crossover rheumatoid arthritis inflammatory bowel disease similar arthritic symptom mechanisms inflammation . There limited investigation gut bacteria rheumatoid arthritis , animal work show treatment probiotic prebiotics improve condition . The aim study examine bacteria stool woman pregnant rheumatoid arthritis identify significant bacteria change might use direct future research .</brief_summary>
	<brief_title>Faecal Calprotectin Potential Non-invasive Inflammatory Marker Pregnancy Inflammatory Bowel Disease</brief_title>
	<detailed_description>Pregnancy interest different impact inflammatory condition much common immunologically . In inflammatory bowel disease 33 % deteriorate , 33 % remain stable 33 % improve . In rheumatoid arthritis 75 % woman improve . Gut microbiota alters significantly pregnancy predominant immunological pathway relapse post-partum swift . Research intestinal microbiota woman inflammatory condition scant . The high remission rate pregnancy give u unique opportunity study microbiota change pattern could identify future potential therapeutic target . The study aim identify bacterial change pre-conception pregnancy post-partum compare woman relapse rheumatoid arthritis remain remission . Clinical condition assess stool serum sample obtain woman trim pregnancy analysis serum fecal biomarkers microbiota 16S rRNA ( ribosomal ribonucleic acid ) technique . Group-specific 16S rRNA-targeted oligonucleotide probe label fluorescent dye Cy3 use enumerate bacteria . The probe use determine bifidobacteria , bacteroides , clostridia ( Clostridium perfringens/histolyticum sub . Grp . ) , eubacterium recale-C histolyticum sub gp. , agrobacterium rima - Collinsella-Eggerthella lenta sub . Gp. , Lactobacillus/Enterococcus spp. , desulfovibrio spp. , Faecalibacterium prausnitzii Escherichia coli , interferon-gamma Interleukin 10 ( IL-10 ) . Total bacteria enumerate use flow cytometry technique . The outcome project would help identify microbiota pattern bacteria specie beneficial rheumatoid arthritis could target potential gut immunomodulation therapy future prolong period remission .</detailed_description>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<criteria>Healthy pregnant woman ( i.e . noIBD significant comorbidities ) . pregnant IBD rheumatoid woman class disease activity , nonpregnant IBD woman Rheumatoid arthritis woman age 18 40 . Coeliac disease Familial adenomatous polyposis hereditary nonpolyposis Rheumatoid arthritis ( healthy group IBD group ) Irritable bowel syndrome ( ROME III criterion ) Lactose intolerance Other connective tissue inflammatory disease Active infection NSAID , aspirin anticoagulant u , Recipients antibiotic 4 week initial trial participation Women oral contraceptive pill</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Inflammatory Bowel Disease</keyword>
	<keyword>Pregnancy</keyword>
	<keyword>Stool marker</keyword>
	<keyword>Calprotectin</keyword>
	<keyword>Faecal S100A12 ( f-SA12 )</keyword>
	<keyword>Faecal calprotectin ( f-Cp )</keyword>
</DOC>